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http:WHAT THIS PAPER ADDS
Currently, there is little knowledge on the optimal duration of compression stocking use after endovenous GSV
ablation in terms of efﬁcacy, but also in terms of patient satisfaction. This study demonstrates that pain is signif-
icantly reduced during the ﬁrst week in the group of patients wearing the stockings for 7 days when compared with
2-day use. Also, physical function and vitality were better in the group of patients with 7-day use of stockings. No
differences in results and complication rates were observed after 3 months. This studymay change clinical practice
as patients can be better informed on the possible counterpart of a short duration of stocking wear.Objectives: To determine if the duration of wearing compression stockings after endovenous laser ablation
(EVLA) of the great saphenous vein (GSV) has inﬂuence on pain and quality of life.
Methods: This was a prospective randomized controlled trial. Between December 2006 and February 2008, 109
consecutive patients with EVLA of the GSV were analyzed. Deep vein insufﬁciency, ulceration, more than one
insufﬁcient vein in one leg, and use of anticoagulants were exclusion criteria. Group A used compression stocking
for 48 hours after therapy, group B for 7 days. Pain (visual analogue scale [VAS]) and quality of life (SF-36) were
analyzed 48 hours, 1 week, and 6 weeks after therapy. Three months after treatment, duplex ultrasound imaging
was performed to assess occlusion rates.
Results: Both groups (group A, n ¼ 37; group B, n ¼ 32) where comparable at baseline.
After 1 week, there was a signiﬁcant difference in pain (VAS score 3.7 [2.1] vs. 2.0 [1.1], p  .001), and
physical dysfunction (group A, 85.1 [11.2] vs. group B, 95.7 [10.1]; p < .001) as well as vitality (group A, 75
[13.0] vs. group B, 83.7 [13.4]; p ¼ .03), all in favor of group B, which disappeared after 6 weeks. After 6
weeks, no signiﬁcant differences in all endpoints were present. Duplex ultrasound imaging revealed complete
GSV occlusion in all patients, while no cases of deep venous thrombosis had developed.
Conclusions: Prescribing compression stockings for longer than 2 days after endovenous GSV ablation (without
simultaneous phlebectomies) leads to reduced pain and improved physical function during the ﬁrst week after
treatment.
 2013 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.
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Great saphenous vein (GSV) incompetence is the most com-
mon cause of chronic venous insufﬁciency. Associated symp-
toms range from mild conditions such as fatigue, heaviness,
and itching to more serious conditions such as skin discolor-
ation and leg ulceration. Over the last years, signiﬁcant ad-
vances in GSV ablation using percutaneous techniques have
emerged, includingendovenous laser ablation (EVLA). EVLAhasresponding author. R.J. Hissink, Department of Surgery, Scheper
l Emmen, P.O. Box 30.002, 7800 RA Emmen, The Netherlands.
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//dx.doi.org/10.1016/j.ejvs.2013.08.001replaced surgical treatment by high ligation and stripping (HL/
S) in many centers worldwide, due to greater patient satisfac-
tion (ofﬁce-based treatment, no incisions, faster recovery) and
cost-effectiveness (no admission, no use of operation room
facilities). The randomized controlled trials performed so far
have shown equal results (at least) in terms of outcome,1e5
even in the long term.2,6e8 Compression stockings are
frequently prescribed after HL/S in order to reduce pain and
other associated symptoms.9 It is unclear, however, whether
this leads to any clinically observable beneﬁt to the patient.10
In addition, the optimal duration of wearing compression
stockings after HL/S or EVLA is unclear. One prospective
study assessed the need to wear additional compression
stockings for 4 weeks after inversion stripping of the GSV
from the groin to the level of the knee.11
Figure 1. Flowchart of patient enrolment.
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additional beneﬁt following elastic bandaging for 3 days in
postoperative care after stripping of the GSV as assessed by
control of limb edema, pain, complications, and time to return
to work.
In patients treated with EVLA, no studies on the duration
of wearing compression stockings have been performed so
far.12 One study prospectively evaluated the effect of
eccentric compression applied by a crossed-tape technique
on procedure-related pain occurrence after EVLA of the
GSV. It showed that the intensity of postoperative pain was
signiﬁcantly reduced in the eccentric compression group
compared with the non-compression one.10
It was our observation that many patients experience
inconvenience when wearing compression stockings for a
longer period of time. Therefore, our aim was to investigate
whether shortening the duration of wearing compression
stockings after EVLA had any inﬂuence on outcome in terms of
pain and quality of life.We therefore conducted a prospective,
randomized controlled trial, inwhichpatientswere randomized
to wear compression stockings postoperatively for 2 or 7 days.
In addition, all patients underwent duplex ultrasound imaging
of the GSV 3 months after treatment to study the deﬁnitive
occlusion rate in both groups to conﬁrm that the period of
compression had no inﬂuence on the occlusion rate after EVLA.MATERIALS AND METHODS
Patients
This prospective randomized controlled trial took place
from December 2006 until February 2008. A total of 109
consecutive patients were included. All patients were
treated at the Center of Phlebology Emmen, a specialized
outpatient clinic for treatment of lower limb venous dis-
ease. Patients were considered eligible for inclusion if they
were between 18 and 65 years of age with symptomatic
varicose veins due to GSV insufﬁciency. Exclusion criteria
were deep venous insufﬁciency, coexistence of an ulcus
cruris, use of anticoagulants or antiplatelet therapy, pres-
ence of more than one potentially treatable insufﬁcient
vein. After discussion with the institutional review board,
ethical approval was not considered necessary as no addi-
tional invasive or other medical treatments were applied to
the intervention group. Still, written informed consent was
obtained from all patients.
Finally, 69 of the 109 included patients were analyzed.
Forty patients were excluded because of incomplete
informed consent (n ¼ 12), no proper treatment (n ¼ 7),
early release of stockings (n ¼ 4), incomplete SF-36 (n ¼ 7),
lost to follow-up (n ¼ 6), other (n ¼ 4). The ﬂowchart ac-
cording to the CONSORT statement is shown in Fig. 1.
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After informed consent was obtained, patients were ran-
domized into two groups before the start of treatment.
Patients received a numbered sealed envelope at the day of
treatment stating to which group they were allocated. This
numbered envelope was blindly provided by one of the
research nurses. At follow-up after 48 hours, 1 week, and 6
weeks of treatment, providers were still blinded. Both
groups (A, n ¼ 37; B, n ¼ 32) were equal in baseline patient
characteristics (age, sex, surgeon, clinical [part C of the
Clinical, Etiologic, Anatomic, and Pathophysiologic] classiﬁ-
cation, and length of the insufﬁcient GSV) (Table 1).
Group A (intervention group) wore compression stock-
ings for 48 hours after treatment, while group B (control
group) wore compression stockings for 7 days after
treatment.
All patients were followed for 3 months after initial
treatment. The visual analogue scale (VAS) for pain was
recorded at 48 hours, 1 week, and 6 weeks. The SF-3613 was
scored, and physical examination was done at 1 week and 6
weeks. The physician assistant performing the follow-up was
blinded to which group the patients were allocated. Oc-
clusion rates were assessed at 3 months to see if there was
any suggestion that the duration of compression might in-
ﬂuence occlusion rates.Treatment
Patients were treated in the supine position. The usual
puncture site was 5e10 cm below the knee. The entire
procedure was performed under duplex ultrasound guid-
ance (Philips iU22 ultrasound system, Philips medical sys-
tems, The Netherlands). All patients were treated with a
810-nm diode laser with a bare-tip ﬁber (Diomed delta
15W; Andover, MA, USA), continuous mode, 14 W, deliv-
ering 70 J/cm. Perivascular local tumescent anesthesia
(500 mL of NaCl 0.9%, 33 mL of lidocaine 1% with
epinephrine (adrenaline) 1:200.000 and 1 mL of NaHCO3
8.4%) was used for the GSV. Additional sclerotherapy or
phlebectomies were not performed simultaneously.
After treatment, the circumference of the ankle, the
lower leg, the knee, and the upper leg was measured in
order to estimate the size of the compression stocking
(Mediven Struva, AG hip, 35 mmHg) the patient should
wear. They were ﬁtted directly after treatment by the same
person (RGB), and worn continually day and night until
removal. Patients were advised to walk regularly (at least 3
times daily for 20 minutes) and prescribed standardTable 1. Patient characteristics.
Group A SD Group B SD p Value
Age (years) 49.5 12.7 51.3 11.1 NS
Weight (kg) 78.4 11.1 81.6 13.6 NS
Length (cm) 173 7.8 169 7.7 NS
GSV length (cm) 45.6 10.3 48.1 10.6 NS
C of CEAP 2.3 0.65 2.4 0.94 NS
CEAP ¼ Clinical, Etiologic, Anatomic, and Pathophysiologic;
GSV ¼ great saphenous vein.Diclofenac (50 mg 3 times a day) during 10 days post-
procedure. Pharmacological prophylaxis for deep venous
thrombosis was not provided.Endpoints
Primary outcome measures were quality of life as measured
by the SF-36 questionnaire and pain (VAS score) at each
visit. In addition, an ultrasound was performed 3 months
after treatment to check occlusion of the treated GSV and
the deep venous system. Also, postoperative morbidity
(hematoma, occurrence of thrombophlebitis, edema) was
assessed.Statistics
Continuous variables were expressed as mean with stan-
dard deviation or median with range, and categorical vari-
ables as counts and percentages. The ShapiroeWilk test,
together with normality plots were used to assess normal
distribution of the continuous variables. Differences be-
tween groups were evaluated by the Student t test or
ManneWhitney U test for continuous data and by the
Fisher exact test or c2 test for categorical data. A post hoc
power analysis with a ¼ .05 was performed to identify
whether enough patents had been enrolled to show any
signiﬁcant differences in the primary outcome measures. A
two-tailed p < .05 was considered to indicate statistical
signiﬁcance. All analyses were performed using SPSS 20.0
for Windows (SPSS Inc., Chicago, IL, USA).RESULTS
Quality of life (SF-36)
At 1-week follow-up, physical function (group A 85.1
[11.2] vs. group B 95.7 [10.1]; p  .001) and vitality
(group A 75 [13.0] vs. group B 83.7 [13.4]; p ¼ .03) were
both signiﬁcantly better in group B. A post hoc power
analysis for these outcome variables showed a power of
98.5 and 77.8%, respectively. At 48 hours and 6 weeks
postoperatively, no signiﬁcant differences were observed
between both groups (Tables 2 and 3).Pain
At the ﬁrst measurement, 48 hours postoperatively, no
statistically signiﬁcant differences were observed between
the VAS scores in both groups. After 1 week, though, the
VAS score in group A (2 days of stocking wear) was signif-
icantly higher than patients in group B (VAS score 3.7 [2.1]
vs. 2.0 [1.1]; p  .001, Table 2). A post hoc power analysis
showed a power of 98.5% (a ¼ 0.05) for this outcomeTable 2. Visual analogue scale score (pain).
Time Group A SD Group B SD p Value
48 h 3.2 1.6 3.4 2.1 NS
1 week 3.7 2.1 2.0 2.0 <.001
6 weeks 1.6 1.3 1.9 2.0 NS
Table 3. Quality of life after 1 week and 6 weeks (SF-36).
Quality of life (SF-36) Group 1 week 6 weeks
Mean SD p Value Mean SD p Value
Physical function A 85 11.21 <.001 97 6.38 NS
B 96 10.06 96 9.92
Social function A 84 16.51 NS 99 3.12 NS
B 94 17.08 99 3.12
Role physical A 73 37.44 NS 95 13.57 NS
B 88 29.25 86 31.04
Role emotional A 86 30.89 NS 98 11.97 NS
B 96 13.87 94 17.79
Mental health A 88 8.76 NS 91 7.15 NS
B 92 8.36 91 8.33
Vitality A 75 13.30 .03 82 12.95 NS
B 83 13.36 82 13.53
Pain A 66 21.19 <.001 87 12.30 NS
B 86 17.98 84 20.04
General health A 79 11.00 NS 82 12.01 NS
B 84 14.36 84 14.25
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weeks’ follow-up.
After 3 months, 100% occlusion of the GSV in both
groups was seen by duplex ultrasound imaging, while none
of the patients developed deep vein thrombosis in both
groups.Morbidity
The morbidity rate was comparable in both groups at all
times: 22 patients (61.1%) in group A suffered from post-
operative morbidity after 1 week (only hematoma),
compared with 14 patients (50.0%) in group B (p ¼ .36).
DISCUSSION
As GSV incompetence is a commonly observed medical
problem all over the world, many physicians are faced by
this problem. Although treatment strategies have evolved
over the last decades, with the introduction of effective
minimal invasive percutaneous techniques such as EVLA,
postoperative care is still not standardized due to a lack of
feasible studies. In this prospective randomized trial it is
clearly demonstrated that wearing elastic stockings after
EVLA for more than 2 days does not lead to any clinically
observable beneﬁt after 6 weeks while occlusion rates as
measured by duplex ultrasound imaging are comparable.
Also, complication rates are comparable.
However, postoperative pain is signiﬁcantly reduced
when measured 1 week after treatment and also the
physical function and vitality (as measured by the SF-36) is
signiﬁcantly better in the group of patients wearing the
stockings for 1 week. To the best of our knowledge this is
the ﬁrst study directly comparing the duration of wearing
compression stockings after EVLA.
Some study limitations have to bementioned. It is clear that
the present results only apply to patients in whom GSV
incompetence is treated by EVLA. It is important to recognize
that this was a feasibility study and that results in terms of
efﬁcacy cannot be provided as the present study isunderpowered. For such a study, given a 95.0% efﬁcacy rate of
EVLA (occlusion after 3 months, yes/no), and detecting an
absolute difference of 5.0% in efﬁcacy, a minimal of 868 pa-
tients should have been enrolled. The duplex ultrasound at 3
months’ follow-up was performed to assess the safety of the
different patient categories, not to analyze superiority of one
of the protocols in terms of efﬁcacy. Also, it is obvious that our
results cannot be generalized to other treatment options for
GSV incompetence such as phlebectomies or sclerotherapy.
Also, if phlebectomies are to be performed simultaneously, our
resultsmight not beapplicable. Another limitation is the loss of
40 patients after randomization due to a variety of reasons. As
the number of patients included is relatively small, we cannot
exclude that different results may have shown up without the
loss of follow-up of these patients. In addition, four patients in
the control group (group B, stockings for 7 days) discontinued
stocking wear early. These patients were not analyzed. How-
ever, if these patients had been analyzed on an intention to
treat base, this might have inﬂuenced the results. Patient
adherence to prescribed postoperative medication was not
assessed regularly, as such we cannot exclude that this might
also inﬂuence results in terms of pain. Another issue that
needs to be addressed is the kind of laser and tip used. Itwould
be interesting to knowwhether newer laser generations or the
use of another tip another tip14might have led toother results.
Further research is warranted in this area.
Nevertheless, in our opinion, the results of the present study
are important for patients and their physicians. Fromamedical
point of view, compression stockings do not have to be pre-
scribed for more than 2 days, as clinical results and morbidity
rates seem to be comparable in both groups. Pain and quality
of life are among the most important parameters when it
comes to patient satisfaction, however.We can therefore not
ignore the observation that 7-day use of compression stock-
ings leads to better results in terms of these parameters. We
therefore suggest the following algorithm: the patient should
wear compression stockings after EVLA for at least 48 hours
after treatment. After careful informed consent, in which the
patient is informed on the possible consequences, the patient
592 N.A. Bakker et al.is then free to decide whether the inconvenience of wearing






APPENDIX A. SUPPLEMENTARY DATA
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.ejvs.2013.08.001.REFERENCES
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